Why BridgeWell
is different
We built BridgeWell because the GLP-1 revolution created a massive gap: platforms that get people started, but no one designed to help them finish.
GLP-1 adoption is exploding.
Long-term outcomes are not.
GLP-1 medications are among the most effective obesity treatments ever developed. But clinical trial data reveals a critical problem: when patients stop — whether due to cost, supply, or clinical guidance — most regain the majority of lost weight within 12 months without sustained support.
The telehealth companies that rushed into GLP-1 prescribing are optimized for patient acquisition and prescription volume. They are not optimized for what comes after the first injection — and that's where BridgeWell lives.
A platform, not a clinic
BridgeWell owns the member experience, care journey, and long-term outcomes layer. Clinical services come from our partner provider networks — meaning we scale without the cost structure of a traditional clinic.
What BridgeWell owns
- ✓ Brand & member relationship
- ✓ Onboarding & intake experience
- ✓ Member portal & care journey
- ✓ Taper & maintenance protocols
- ✓ Coaching & accountability layer
- ✓ Retention & relapse prevention
What partners provide
- → Licensed clinicians (CareValidate)
- → Prescription & clinical oversight
- → Lab review & monitoring
- → Registered dietitians (Fay)
- → Health coaching (inHealth)
- → Guided movement library
Why this works
- ⚡ Faster to scale without hiring clinicians
- ⚡ Better unit economics than in-house model
- ⚡ Access to multi-state licensed providers
- ⚡ Focus on experience, not clinic overhead
- ⚡ Outcome accountability stays with BridgeWell
Why BridgeWell is harder to copy
than a prescription platform
The care model is the moat
A prescription platform's only differentiation is price and speed. BridgeWell's differentiation is the integrated care experience — which is operationally difficult to replicate quickly and builds genuine member loyalty.
Maintenance creates recurring revenue
Members who graduate from GLP-1 treatment continue with BridgeWell Maintain. This creates long-term retention revenue that a prescription-only model loses the moment medication stops.
B2B2C creates a second acquisition channel
Employer partnerships give BridgeWell a high-volume, low-CAC channel that prescription-focused competitors aren't designed to serve well — because they can't demonstrate outcomes continuity.
Outcomes data compounds over time
As BridgeWell accumulates outcomes data across the full care lifecycle, it builds a clinical evidence base that strengthens the brand, supports employer sales, and enables future product expansion.
See the full program
Learn exactly how BridgeWell guides you from initial assessment through treatment, tapering, and long-term maintenance.